Why your sector is affected
Most large pharmaceutical companies are Category A with high Scope 3 share and strong stakeholder attention on supplier evidence.
Likely Scope 3 hotspots
- Active pharmaceutical ingredients and excipients.
- Contract development and manufacturing organisations.
- Capital goods for production and R&D facilities.
- Use of sold products for inhalers and other propellant based devices.
Supplier evidence to prepare
- Supplier specific data for top API and CDMO partners.
- Documented methodology for use phase emissions where relevant.
- Source linked numbers ready for assurance and reporting.
Procurement actions that move the needle
- Embed climate criteria into CDMO and API selection.
- Engage major suppliers on supplier specific data.
- Prioritise low carbon device and packaging innovation.
Want a personalised view for your company? Run the SBTi v2 Impact Checker.
Free diagnostic
See how SBTi v2 affects your company
Five minutes. Four scores. A personalised action plan with owners and timing.
Start the checker